IPSEN (OTCMKTS:IPSEY) Receives Average Rating of “Hold” from Analysts

IPSEN (OTCMKTS:IPSEY) has received an average rating of “Hold” from the six brokerages that are currently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and two have issued a buy recommendation on the company.

A number of research analysts have recently commented on IPSEY shares. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of IPSEN in a research note on Thursday, May 14th. Jefferies Financial Group cut IPSEN from a “hold” rating to a “moderate sell” rating in a research note on Sunday, August 2nd. HC Wainwright reiterated a “buy” rating on shares of IPSEN in a report on Tuesday, June 30th. Finally, Zacks Research raised IPSEN to a “hold” rating in a research report on Friday, May 29th.

IPSEN Stock Performance

IPSEY stock opened at $47.60 on Thursday. IPSEN has a fifty-two week low of $32.02 and a fifty-two week high of $51.10. The business’s 50 day moving average price is $46.06 and its two-hundred day moving average price is $46.39.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).